Clinical trial NCT06954987: Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Official title: A Two Cohort, Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined With Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation Then Venetoclax Maintenance in Adult Patients With Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Acute Myeloid Leukemia
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2025-05-02
Enrollment: 244
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This phase II MyeloMATCH treatment trial compares the effect of adding venetoclax or placebo to reduced intensity conditioning chemotherapy with fludarabine and busulfan or melphalan, with or without total body irradiation, followed by hematopoietic stem cell transplant and either venetoclax or placebo maintenance therapy after transplant, for the treatment of patients with acute myeloid leukemia (AML). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving chemotherapy and total body irradiation before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells. Adding venetoclax to conditioning therapy before, and giving it as maintenance therapy after, a hematopoietic stem cell transplant may be a more effective treatment option than the usual approach in patients with AML.

Detailed description: PRIMARY OBJECTIVE:

I. To determine if venetoclax combined with reduced-intensity conditioned allogeneic hematopoietic cell transplantation improves 100-day event-free survival relative to placebo in adults with AML in first complete remission (complete remission \[CR\] or complete remission with incomplete hematologic recovery \[CRi\]).

SECONDARY OBJECTIVES:

I. To determine the post-transplant 30-day and 12-month event-free survival (EFS) rates in venetoclax and placebo arms.

II. To determine the post-transplant 12-month EFS in patients with minimal/measurable residual disease (MRD)-positive status first complete remission at transplant in venetoclax and placebo arms.

III. To determine the post-transplant 100-day and 12-month overall survival (OS) rate in venetoclax and placebo arms.

IV. To determine the post-transplant 100-day and 12-month cumulative incidence rates (CIR) of morphologic relapse in venetoclax and placebo arms.

V. To determine the post-transplant 100-day and 12-month non-relapse mortality (NRM) rates in venetoclax and placebo arms.

VI. To determine the post-transplant 12-month relapse-free survival rate (RFS), OS, cumulative incidence of relapse (CIR), and cumulative incidence of NRM from start of maintenance in venetoclax and placebo arms.

VII. To determine the post-transplant 100-day and 12-month cumulative incidence of grade 2-4 acute graft versus host disease (GVHD) and 12-month cumulative incidence of chronic GVHD.

VIII. To determine neutrophil engraftment at day 30 and platelet engraftment at days 30 and 60 post-transplant.

IX. To determine the incidence of primary and secondary graft failure within 12 months of hematopoietic stem cell transplant (HCT).

X. To assess toxicity and tolerability of the combination of reduced intensity conditioned allogeneic hematopoietic cell transplantation and venetoclax.

EXPLORATORY OBJECTIVES:

I. To determine the post-transplant 30-day MRD clearance rates in venetoclax and placebo arms.

II. To assess patterns of immune reconstitution per standard of care (SOC) site testing for venetoclax and placebo arms.

III. To assess patterns of marrow and peripheral blood chimerism per SOC site testing for venetoclax and placebo arms.

IV. To assess graft-versus-host relapse-free survival for venetoclax and placebo arms.

V. To assess clinical flow and genetic MRD concordance rate (using Myelomatch available MRD tools) and to associate MRD negativity with clinical outcomes for venetoclax and placebo arms.

VI. Compare rate of cytokine release syndrome after hematopoietic cell infusion. (Cohort 2 only)

OUTLINE: Patients with matched donors are randomized to conditioning 1A or 1B. Patients with haploidentical or mismatched unrelated donors are randomized to conditioning 2A or 2B.

CONDITIONING 1A: Patients receive venetoclax orally (PO) once daily (QD) on days -10 to -2, fludarabine intravenously (IV) on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or twice daily (BID) on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

CONDITIONING 1B: Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

CONDITIONING 2A: Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

CONDITIONING 2B: Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: All patients without evidence of relapse at day +100 are re-randomized to maintenance I or II.

MAINTENANCE I: Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.

MAINTENANCE II: Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.

Patients undergo chest x-ray, echocardiography or multigated acquisition scan (MUGA) during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo positron emission tomography (PET) scan and/or computed tomography (CT) scan throughout the study.

After completion of study treatment, patients are followed up at 30 days, every 3 months for up to 1 year and then every 6 months for up to 10 years.

Eligibility criteria: Inclusion Criteria:

* Patients must be registered to the Master Screening and Reassessment Protocol (MSRP) and assigned to this protocol by the MATCHBox Treatment Verification Team
* STEP 1: History of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria in first complete remission with morphologic complete remission (CR) or CR with incomplete hematologic recovery (CRi) defined as less than 5% bone marrow blasts by morphology with no circulating leukemic myeloblasts and no known extramedullary disease
* STEP 1: MRD status by MDNet must have been performed
* STEP 1 COHORT 1: Human leukocyte antigen (HLA)-matched donor defined as one of the following:

  * Sibling donor must be a 6/6 match at HLA-A and -B (intermediate or higher resolution) and -DRB1 (at high resolution using deoxyribonucleic acid \[DNA\]-based typing)
  * Related donor other than sibling must be an 8/8 match for HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing
  * Unrelated donor must be an 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing
  * Age 40-75 years
* STEP 1 COHORT 1: Not recommended for a myeloablative regimen by treating investigator
* STEP 1 COHORT 2: Haploidentical or HLA-mismatched unrelated donor defined as one of the following:

  * Haploidentical donors: Related donor must be a haploidentical 3/6, 4/6, or 5/6 match at HLA-A and -B (intermediate or higher resolution) and -DRB1 (at high resolution using DNA-based typing)
  * HLA-mismatched unrelated donors: Unrelated donor must be a 6/8 or 7/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing, ideally age \< 35
  * Age 18-75 years
* STEP 1 COHORT 2: Not recommended for a myeloablative regimen by treating investigator
* STEP 1: Prior venetoclax therapy is allowed unless there is evidence of progression or no response (failure to achieve remission) to venetoclax-based regimen \< 2 months prior to registration
* STEP 1: No prior allogeneic or autologous hematopoietic cell transplantation
* STEP 1: Anti-leukemic therapy must be completed more than 14 days prior to registration with the exception of venetoclax
* STEP 1: Karnofsky performance status ≥ 60
* STEP 1: Total bilirubin \< 2 x upper limit of normal (ULN)
* STEP 1: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) \< 3 x upper limit of normal (ULN)
* STEP 1: Alkaline phosphatase ≤ 2.5 x upper limit of normal (ULN)
* STEP 1: Pulmonary function diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ≥ 40% and forced expiratory volume (FEV1) ≥ 50%
* STEP 1: Calculated (Calc.) creatinine clearance ≥ 40 mL/min/based on the Cockcroft-Gault formula
* STEP 1: Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 7 days prior to registration is required
* STEP 1: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* STEP 1: Patients with known HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
* STEP 1: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
* STEP 1: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
* STEP 1: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association (NYHA) Functional Classification. To be eligible for this trial, patients should have ejection fraction ≥ 40% and NYHA functional status class II or better
* STEP 1: No history of liver cirrhosis
* STEP 1: No history of sinusoidal occlusion syndrome of the liver
* STEP 1: No known intolerance or allergy to any protocol-defined agents
* STEP 1: No known medical condition causing an inability to swallow oral formulations of agents
* STEP 2: Patient has completed the conditioning and transplantation regimens
* STEP 2: Patient has no evidence of AML morphologic relapse
* STEP 2: Patient does not have flow measurable/minimal residual disease by myeloMATCH central labs (MDNet) testing defined as ≥ 0.1% on day 100+ (between day 80+ and 110+) marrow
* STEP 2: Absolute neutrophil count \> 1,000/mcL (confirmed by a lab draw performed on two separate occasions \[\> 2 days apart\])
* STEP 2: Platelet count \> 50,000/mcL
* STEP 2: AST (SGOT)/ALT (SGPT) \< 3 x upper limit of normal (ULN)
* STEP 2: Total bilirubin \< 2 mg/dL x upper limit of normal (ULN)
* STEP 2: Calc. creatinine clearance ≥ 40 mL/min/based on the Cockcroft-Gault formula
* STEP 2: Patient does not have active/current grade 3-4 acute GVHD
* STEP 2: Patient does not have evidence of grade 3 or higher sinusoidal occlusion syndrome/veno-occlusive disease of the liver as defined by European Society for Blood and Marrow Transplantation (EBMT) criteria

Primary outcomes:
measure: Event free survival (EFS)
timeFrame: From randomization to minimal residual disease (MRD) persistence, MRD relapse, morphologic relapse, or death from any cause, assessed up to day +100
Secondary outcomes:
measure: MRD conversion rate
timeFrame: At day +30
measure: EFS
timeFrame: From the time of randomization to relapse or death, assessed at 12 months
measure: Overall survival
timeFrame: From randomization to death from any cause, assessed up to 10 years
measure: Relapse free survival
timeFrame: From randomization or re-randomization to morphologic relapse or death from any cause, assessed up to 10 years
measure: Non relapse mortality
timeFrame: From randomization to death from any cause other than morphologic relapse, assessed up to 10 years
measure: Cumulative incidence of morphologic relapse
timeFrame: From the date of achievement of a remission until the date morphologic relapse, assessed up to 10 years
measure: Incidence of acute graft versus host disease (GVHD)
timeFrame: From date of randomization until date of death with acute GVHD
measure: Incidence of chronic GVHD
timeFrame: From date of randomization until date of death with chronic GVHD
measure: Time of neutrophil engraftment
timeFrame: Up to 10 years
measure: Time of platelet engraftment
timeFrame: Up to 10 years
measure: Incidence of adverse events
timeFrame: Up to 10 years
Other outcomes:
Locations:
Study officials:
affiliation: Alliance for Clinical Trials in Oncology
name: Matthew J Wieduwilt
role: PRINCIPAL_INVESTIGATOR
References: